Increasing contrast agent concentration improves enhancement in first-pass CT perfusion.
OBJECTIVE
Our aim was to evaluate whether increasing iodine concentration, at a constant total iodine dose, resulted in better brain tissue opacification in patients with acute stroke symptoms during their evaluation by first-pass CT perfusion (CTP).


METHODS
One hundred two patients presenting to the emergency department within 3 hours of onset of acute stroke symptoms underwent CTP scanning. Three different concentrations of iodinated nonionic contrast material were used (300, 350, or 400 mg/mL). Total iodine dose (15 g) and injection rate (7 mL/s) were kept constant. There were 25, 53, and 19 patients in the different concentration groups, respectively; 5 patients were excluded due to uncorrectable motion artifacts. CTP scanning was performed at the level of the putamen, and data were analyzed by determining peak opacification for normal gray and white matter, arterial input, and venous output. Mean and SD values were calculated, and 3 concentration groups, stratified by region-of-interest location, were compared by using a single-tailed unpaired t test.


RESULTS
Monotonic increasing peak opacification was observed in all region-of-interest locations. Statistically significant differences were observed between the 300 and 350 mg/mL, 300 and 400 mg/mL, as well as the 350 and 400 mg/mL groups (P<.01) in white matter, gray matter, and the arterial input. Statistical significance was seen in the venous output group between the 300 and 400 mg/mL (P<.005) and 350 and 400 mg/mL (P<.007) groups, but not between the 300 and 350 mg/mL (P=.2) groups.


CONCLUSIONS
Increasing contrast concentration improves peak opacification of tissue, suggesting that CTP evaluation of patients with acute stroke is better performed with the highest available concentration contrast agent.
Silvennoinen
H M
HM
Department of Radiology-Neuroradiology, Helsinki University Central Hospital, Helsinki, Finland. heli.silvennoinen@hus.fi
Hamberg
L M
LM
Valanne
L
L
Hunter
G J
GJ
D000368:Aged; D003287:Contrast Media / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007472:Iohexol / Q000008:administration & dosage*; D007479:Iopamidol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008297:Male; D010477:Perfusion; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
D003287:Contrast Media; C057937:iomeprol; D007472:Iohexol; D007479:Iopamidol
Neuroimaging Clin N Am. 2005 Aug;15(3):481-501, ix
16360585
AJNR Am J Neuroradiol. 1996 Apr;17(4):639-50
8730182
Radiology. 2004 Dec;233(3):682-8
15486215
AJNR Am J Neuroradiol. 2000 Sep;21(8):1441-9
11003276
Magn Reson Imaging. 1997;15(3):307-17
9201678
AJR Am J Roentgenol. 2003 Jan;180(1):3-12
12490467
Radiology. 2004 May;231(2):587-93
15064388
Neuroradiology. 2004 Sep;46(9):705-15
15300343
AJR Am J Roentgenol. 2005 Jun;184(6):1935-9
15908557
Acad Radiol. 2004 Oct;11(10):1085-92
15530801
Stroke. 2003 Apr;34(4):1084-104
12677088
Radiology. 1999 Oct;213(1):141-9
10540654
Radiology. 2005 Aug;236(2):661-5
16040923
Radiology. 2004 Jun;231(3):632-44
15118110
Eur Radiol. 2004 Nov;14(11):2099-104
15309493
AJNR Am J Neuroradiol. 2005 Jan;26(1):104-12
15661711